Abstract
e13037 Background: Optimal treatment of patients with bulky or multifocal glioblastoma, or with severe neurological impairment is not well established. We evaluated here the impact of upfront Temozolomide (TMZ) and bevacizumab (BEV) in such patients. Methods: This retrospective study included 43 patients from 3 French centres between December 2010 and December 2014. Patients were considered not eligible for surgery or initial chemoradiation either due to tumor volume precluding an upfront chemoradiotherapy with TMZ, or due to multifocality or severe neurological impairment. Initial combination of TMZ (150 to 200 mg/m2/d, 5d every 28d) plus BEV (10mg/kg every 14d) was delivered. Responding patients received radiotherapy (60 Gy in 30 fractions) plus concomitant TMZ (75mg/m2/d), with or without BEV (10mg/kg every 14d). Results: Forty-three patients were analyzed (median age 60 years, median Karnofsky Performance Status (KPS) 70). Thirty-two patients (74%) were classified in the RTOG RPA group V-VI. Median nu...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
